
A judge approved a settlement on Friday for up to $7.25 billion to settle thousands of lawsuits against the German pharmaceutical and agrochemical giant Bayer over the alleged carcinogenic effects of its Roundup herbicide, one of the most widely used products for weed control.
Judge Timothy Boyer of a state court in St. Louis, Missouri, granted final approval to the settlement, which seeks to compensate people diagnosed with non-Hodgkin's lymphoma, a type of cancer that affects the lymphatic system, after being exposed to the product.
As reported by Reuters, the ruling represents a significant step forward for Bayer, which has faced thousands of Roundup-related lawsuits since acquiring Monsanto in 2018.
The settlement ranks among the largest class-action personal injury settlements in U.S. history, according to the Associated Press.
How much will people affected by Roundup receive?
Compensation for those who have already been diagnosed with non-Hodgkin lymphoma will range from $10,000 and $165,000, depending on factors such as the type and duration of exposure, as well as whether the herbicide was used at home or at work.
The settlement also covers individuals exposed to Roundup before Feb. 17, 2026, who have not yet developed the disease but who receive a diagnosis within 16 years of the final approval, provided they meet the established requirements.
According to the official statement from Bayer, Monsanto will fund the compensation through capped and decreasing annual payments over a maximum period of 21 years, up to a total of $7.25 billion.
Christopher Seeger, the plaintiffs' lead attorney, welcomed the decision and told AFP that the settlement represents one of the few effective ways for many affected individuals to receive compensation.
Does the glyphosate in Roundup cause cancer?
Roundup's active ingredient, glyphosate, has been at the center of a scientific and legal debate for years regarding its potential health effects.
In 2015, the International Agency for Research on Cancer (IARC), a specialized agency of the World Health Organization (WHO), classified glyphosate as probably carcinogenic to humans, based on limited evidence of cancer in humans and sufficient evidence in laboratory animals.
However, the U.S. Environmental Protection Agency (EPA) has maintained a different assessment and considers that glyphosate is unlikely to cause cancer in humans when used as directed.
Bayer denies that Roundup is carcinogenic and maintains that scientific and regulatory assessments support its safety. The company has also noted that the settlements do not constitute an admission of liability.
Bayer seeks to put an end to years of litigation
Since acquiring Monsanto for approximately $63 billion in 2018, Bayer has set aside billions to settle Roundup-related claims.
The company believes that court approval of the new settlement, along with a U.S. Supreme Court decision issued in June regarding lawsuits over a lack of warnings on labels, could help reduce its exposure to current and future litigation.
In a statement, Bayer CEO Bill Anderson described the final approval as a decisive step in the company's strategy to manage the legal risks associated with Roundup.
As part of its efforts to reduce litigation, Bayer began phasing out Roundup formulations containing glyphosate from the U.S. residential market in 2023, although the compound continues to be used in the agricultural sector.
The approved settlement does not automatically bring all lawsuits against Bayer to a close, but it establishes a long-term compensation mechanism for a broad group of claimants and represents a significant step forward in one of the most costly legal battles in the agrochemical industry.

